Novel Targeted Therapies in CLL Might Expand Treatment Options Medscape Other studies with the novel agent in CLL are underway, including a phase 2 monotherapy study in patients with relapsed CLL and 17p deletions and combination studies with rituximab or obinutuzumab (GA101) in patients with relapsed CLL. Dr. Flinn ... Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B ... Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin ... |
